Harvey Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.54M Sell
6,287
-86
-1% -$87.9K 1.55% 17
2026
Q1
$5.86M Sell
6,373
-305
-5% -$309K 1.34% 19
2025
Q4
$7.18M Sell
6,678
-3
-0% -$2.87K 1.53% 18
2025
Q3
$5.1M Buy
+6,681
New +$4.97M 1.09% 24
2025
Q2
Sell
-975
Closed -$805K 83
2025
Q1
$805K Sell
975
-50
-5% -$41.6K 0.21% 57
2024
Q4
$791K Hold
1,025
0.19% 59
2024
Q3
$908K Hold
1,025
0.23% 53
2024
Q2
$928K Hold
1,025
0.24% 56
2024
Q1
$797K Buy
+1,025
New +$729K 0.23% 55

Other funds holding LLY

Harvey Capital Management's LLY Position: Q2 2026 in Review

Harvey Capital Management reduced its Eli Lilly (LLY) stake by 1.3% in Q2 2026, selling an estimated $87.9K and leaving 6,287 shares worth $7.54M. The position accounts for 1.55% of the portfolio, ranked #17.

Harvey Capital Management first reported a position in LLY in Q1 2024 and has held it in 9 quarters since. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Harvey Capital Management held 6,287 shares of Eli Lilly worth $7.54M as of Q2 2026.
  • Harvey Capital Management sold 86 Eli Lilly shares in Q2 2026, an estimated $87.9K.
  • Eli Lilly made up 1.55% of Harvey Capital Management's portfolio in Q2 2026, its #17 holding.
  • Harvey Capital Management first reported a position in Eli Lilly in Q1 2024 and has held it in 9 quarters since.
  • 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Harvey Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.